Kornimate/medical-research-clean huggingface dataset:
intravitreal aflibercept injection (iai) for presumed ocular histoplasmosis syndrome

Conditions: Choroidal Neovascularization; Presumed Ocular Histoplasmosis

Summary: the purpose of this study is to assess the efficacy and safety of intravitreal injection of aflibercept for the treatment of choroidal neovascularization (cnv) secondary to presumed ocular histoplasmosis syndrome (pohs).


Eligibility criteria:
inclusion criteria: * cnv of less than 1 year duration due to presumed ocular histoplasmosis * ability to provide written informed consent and comply with study assessments for the full duration of the study * age 21 years and older * subfoveal or juxtafoveal cnv lesion of less than 5400um in diameter * best corrected visual acuity of 20/25 to 20/400 * birth control therapy for females of child-bearing age exclusion criteria: * cnv due to presumed ocular histoplasmosis for greater than 1 year * pregnancy (positive pregnancy test) or lactation * premenopausal women not using adequate contraception. the following are considered effective means of contraception : surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an iud, or contraceptive hormone implant or patch * a recent history of smoking (within 1 year of study enrollment) * prior treatment with intravitreal aflibercept injection * any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * uncontrolled glaucoma in the study eye (defined as iop greater or equal to 30 mmhg despite treatment with anti-glaucoma medication) * history of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment * active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * presence of significant subfoveal fibrosis or atrophy * intraocular surgery (including cataract surgery) in the study eye within 2 months of enrollment * active intraocular inflammation (grade trace or above) in the study eye * history of allergy to fluorescein, icg or iodine, not amendable to treatment * any concurrent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, could either * require medical or surgical intervention during the 12 month study period to prevent or treat visual loss that might result from that condition, or * if allowed to progress untreated, could likely contribute to loss of at least 2 snellen equivalent lines of bcva over the 12 month study period * prior/concomitant treatment: * panretinal photocoagulation treatment * previous intraocular steroids or pdt within 3 months * previous participation in any studies of investigational drugs within 30 days preceding day 0 (excluding vitamins and minerals) * previous treatment with intravitreally (in either eye) or intravenously administered avastin (bevacizumab) within 60 days * previous use of macugen or lucentis in study eye within 60 days * prior submacular or vitreous surgery
intraluminal imaging of duodenal layer morphometry in patients with and without type 2 diabetes

Conditions: Type 2 Diabetes

Summary: this observational study is conducted to determine how the duodenal layer thicknesses (mucosa, submucosa, and muscularis) vary with several factors in patients with and without type 2 diabetes.

study objectives 1. to assess duodenal layer (mucosa, submucosa and muscularis) thickness differences between patients with and without type 2 diabetes using endoscopic ultrasound (eus) and optical coherence tomography (oct). 2. to assess duodenal layer thickness differences between patients with type 2 diabetes. 3. to assess duodenal layer thickness differences as a function of measurement location along the length of the duodenum. 4. to compare measurements obtained by endoscopic ultrasound, to those obtained by optical coherence tomography.

Eligibility criteria:
inclusion criteria: * patient is already scheduled for upper endoscopy with ultrasound or oct, such as those with barrett's esophagus. * patient is willing to sign an informed consent form. exclusion criteria: * patient is not a candidate for endoscopy, eus, or oct, such as those with strictures, inflammatory disease or previous anastomosis of the esophagus or duodenum.
dose finding study for effective reversal of a deep rocuronium-induced neuromuscular block with sugammadex in morbidly obese patients

Conditions: Morbidly Obese Patients

Summary: during laparoscopic bariatric surgery, adequate muscle relaxation is important to maintain good surgical conditions. to achieve this muscle relaxation, neuromuscular transmission blocking agents, such as rocuronium (esmeron®) are used. it sometimes happens that there is still some neuromuscular blocking activity left in the patient on awakening from anesthesia. this is called residual curarization and is known to cause postoperative complications such as impairment of respiratory function. sugammadex (bridion®) is a novel drug which selectively binds rocuronium (esmeron®). it allows for reversing of neuromuscular transmission blocking activity. until now, all studies with sugammadex were performed in non-obese patients. obese patient have a high risk to suffer from post-operative respiratory failure. therefore it is vital to avoid residual curarization. sugammadex might be an important factor. obese patients have a large total body weight different from ideal body weight. recent research demonstrated that the dose for the neuromuscular blocking agent rocuronium (esmeron®) needs to be calculated on the patients' ideal body weight rather than on total body weight. at this moment no data is available on the dose-response relationship of sugammadex in morbidly obese patients. we hypothesize that in morbidly obese patients sugammadex should be dosed on ideal bodyweight, instead of total bodyweight.

flowchart : 72 participants stratification bmi\ 50 randomization randomization tbw ibw tbw ibw 2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9 tbw : total body weight ibw : ideal body weight

Eligibility criteria:
inclusion criteria : * asa i-ii-iii * age 18 - 65 year * male or female * bmi \> 30 exclusion criteria : * renal failure * liver dysfunction * breastfeeding female patients, or female patients without reliable contraception * neuromuscular disease * malignant hyperthermia or a family history of malignant hyperthermia * allergy for neuromuscular blocking agents or other medications used during general anesthesia * infectious disease or patients with fever * patients who already received rocuronium or sugammadex on the day of the study
arterial spin labeling blood flow mri for evaluation of response to antiangiogenic and targeted therapies of renal cell carcinoma (rcc)

Conditions: Renal Cell Carcinoma

Summary: the purpose of this study is to assess magnetic resonance imaging (mri) as a tool to track tumor growth for renal cell carcinoma while the participant is receiving clinical treatment therapy with sunitinib or pazopanib. an mri is a sophisticated type of scan that uses powerful magnets to make clearer images or to focus on detailed medical information in the participants abdomen and pelvis. this imaging done for this study will use the asl mri technique that allows us to see blood flow changes which possibly may indicated tumor growth.

* mri's will be performed at specific time points during the participants treatment for renal cell carcinoma with the drug sunitinib or pazopanib. these asl mri's will be performed at baseline, 2 weeks upon initiation of therapy with sunitinib/pazopanib, after cycle 2 and/or cycle 4 of therapy, and at the end of therapy. * the mri tests for all participants will be done at beth israel deaconess medical center.

Eligibility criteria:
inclusion criteria: * patients diagnosed with metastatic renal cell carcinoma and who will initiate sunitinib or pazopanib * enrolled on protocol 06-105, "collection of specimens and clinical data from patients with renal cell carcinoma treated with targeted therapies," or receiving pazopanib as part of routine clinical care. * found to have tumors that are 2.5cm or greater as determined by ct imaging * candidate lesions for asl mri should be 2.5cm or greater. order of preference of lesion location will be as follows: abdominal lesions, bone lesions and chest lesions exclusion criteria: * contraindication to mri

Keywords: mri sunitinib pazopanib
positive effect of ischemic postconditioning during acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the purpose of this study is to determine whether brief periods of ischemia performed just at the time of reperfusion -postconditioning- can reduce coronary endothelial dysfunction and infarct size in humans

desobstruction of the culprit artery after acute myocardial infarction allows to reduce the consequences of prolonged ischemia. however, it is now clearly established that reperfusion induces by itself severe myocardial injuries. postconditioning has been described as an adaptive response triggered by a brief ischemia applied after a prolonged coronary occlusion. several teams have reported that ischemia/reperfusion cycles allow to reduce infarct size in experimental models. different pathophysiological processes have been proposed to explain the beneficial effect of postconditioning. it has been reported that postconditioning reduces the inflammatory response, and activates cardioprotective signaling pathways (akt, enos, p70s6k). in addition, an improvement of the endothelial function has been reported. this controlled trial aim to study the potential beneficial effect of postconditioning in patients with acute myocardial infarction. forty six patients will be included in the study and the culprit artery will be reoccluded three times for 1 minutes after desobstruction in one of the both groups after randomization of the patients. the evaluation will be focused on the comparison of the coronary reserve after intracoronary adenosine injection. in addition, additional parameters will be used to study the effect of postconditioning on post-ischemic endothelial dysfunction: frequencies of low reflow and slow reflow situation, myocardial blush and regression of st elevation. the effect of postconditioning on the left ventricular systolic function will be studied by doppler tissue imaging and rmn.

Eligibility criteria:
inclusion criteria: * acute myocardial infarction (\<6 hours) * occlusion of a major coronary vessel exclusion criteria: * history of previous myocardial infarction * history of coronary artery bypass grafting * need for coronary artery bypass grafting * stenosis not eligible for angioplasty * limited ischemic area * cardiogenic shock * interventricular septum rupture * mitral regurgitation\>2 * ventricular tachycardia * atrioventricular block class ii and iii

Keywords: acute myocardial infarction postconditioning coronary reserve ejection fraction
role of n-acetylcysteine for prevention of cisplatin-induced nephrotoxicity

Conditions: Drug Toxicity

Summary: cisplatin is one of the first-line drugs used against many malignancies, such as lung cancer, head and neck cancer, esophageal cancer, gastric cancer, colorectal cancer, urothelial cancer, bladder cancer and testicular cancer. the usage of cisplatin is limited by its severe nephrotoxicity, which particularly affects the proximal tubule epithelial cells (ptec).several studies suggest role of nac in ameliorating cisplatin induced nephrotoxicity, although definitive data is lacking. n-acetylcysteine (nac) is a thiol-containing antioxidant, which not only acts as a precursor of glutathione but also as a direct antioxidant .there are multiple postulated mechanisms for nac's nephroprotection. nac is a low-cost, easily available drug with a very good safety profile and therefore can be added as a support medication during treatment with cisplatin. the investigators plan to administer 1200 mg oral nac 12 hours before chemotherapy and then daily at night for the subsequent 6 days, with an objective to ascertain its nephroprotective role in population receiving cisplatin/-based chemotherapy.


Eligibility criteria:
inclusion criteria: * adult female outpatients with non-hematological malignancies (breast, ovary and head and neck squamous cell carcinomas) * having eastern cooperative oncology group(ecog) performance status ≤2 who had never received platinum based chemotherapy in past and were now scheduled to receive high-dose cisplatin chemotherapy. * patients were required to have estimated glomerular filtration rate (gfr)(according to cockcroft-gault formula) ≥ 60 ml/min at start of chemotherapy regimen with normal blood counts, liver, and kidney function tests exclusion criteria: * patients who had poor performance status i.e., ecog performance status 3 or 4 * who declined to participate at any time during the course of the study * patients having hepatic failure (liver function tests \>3 times of upper limit normal) * patients who did not tolerate the use of nac or were administered the drug \<70% of the time * patient who were receiving concurrent nephrotoxic drugs, or having history of hypersensitivity to n-acetyl cysteine.
genomic analysis of patients with chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: this study aims to characterize clonal evolution in chronic lymphocytic leukemia (cll) using different approaches and to identify a possible association with disease progression, i.e. therapy initiation. 1. samples this monocentric study is carried out using representative bioarchived leukemic samples with a diagnosis of cll, either at diagnosis or at evolution. these bioarchived samples were collected locally at our center during years of diagnostic activity, and were accurately pathologically, cytogenetically and molecularly characterized. 2. clinical data the clinical data were retrospectively collected through collaboration with the referring physicians. 3. methods samples will be investigated by means of (1) conventional cytogenetics, (2) fluorescence in situ hybridization (fish) and (3) snp-arrays. after analysis of the array data sets, significant results will be validated and in addition, results will be correlated with clinical data.


Eligibility criteria:
inclusion criteria: * diagnosis of cll, * at least two available stored samples exclusion criteria: * at least one inclusion criterium not fulfilled
single port laparoscopic cholecystectomy versus four port laparoscopic cholecystectomy: impact on postoperative pain

Conditions: Postoperative Pain

Summary: this is a single-institution, prospective, randomized controlled trial. subjects determined to need a cholecystectomy will be consented for surgery and study participation prior to enrollment in this study. patients will then be randomized to receive either a single port laparoscopic cholecystectomy or a four port laparoscopic cholecystectomy.

the main advantages of laparoscopic surgery are reduced postoperative pain, shorter hospital stay and the cosmetic result. although reduced, however, pain is still substantial and constitutes the main clinical problem after laparoscopic cholecystectomy, in particular for future daily planned procedures. recently, a new technique of laparoscopic cholecystectomy has been developed, in which all instruments are inserted through the same port placed in the umbilical incision. this technique for cholecystectomy has been proved to be feasible and safe by several studies. the purpose of the study is to compare postoperative pain, operating time, cosmetic result, between one port and standard laparoscopic cholecystectomy.

Eligibility criteria:
inclusion criteria: * biliary cholic * biliary dyskinesia * gallbladder polyps * other diagnosis at the discretion of the surgeon exclusion criteria: * history of acute cholecystitis * jaundice * choledocolithiasis * history of pancreatitis * severe comorbidity * bmi \> 30

Keywords: single port cholecystectomy
serum and urine metabolome studies in patients with acute kidney injury after cardiac surgery

Conditions: Cardiac Surgery Associated Acute Kidney Injury

Summary: the goal of this observational study is to learn about serum and urine metabolome in patients after cardiac surgery.

the main objective of this study is to collect blood and urine samples from patients after cardiac surgery, and to perform metabolomic analysis to find the differential metabolites and their enrichment pathways in aki patients and non-aki patients.the secondary objective is to intervene in its enrichment pathway to find ways to improve csa-aki.

Eligibility criteria:
inclusion criteria: 1. age\> 18 years old; 2. after cardiopulmonary bypass; exclusion criteria: 1. under the age of 18; 2. previous chronic kidney disease or receiving renal replacement therapy; 3. have a history of kidney transplantation or nephrectomy.
perioperative exercise and nutritional optimisation prehabilitation before surgery for patients with peritoneal malignancy

Conditions: Peritoneal Malignancy; Ovarian Cancer; Rectum Cancer; Appendix Cancer; Colon Cancer

Summary: people who are diagnosed with cancer of the colon/rectum/appendix/ovaries that spreads into the lining of the tummy and some ovarian cancers or people with pseudomyxoma peritonei can often undergo intensive treatment including major surgery where chemotherapy is given whilst the person is having surgery - also known by doctors as surgery and hyperthermic intraperitoneal chemotherapy (hipec). fitness for this surgery can improve if people undertake a prehabilitation programme at the time they get their diagnosis. to date, little research has focused on how exercise and nutrition support before surgery can help these patients during recovery. the aim of this study is to explore the use of exercise and nutritional support pre-treatment to enhance physical and psychological outcomes for patients.

the comparator in this study will be standard oncological care. control patients will receive the same care as standard without the addition of a formal exercise and nutrition support programme. the pre-treatment (prehabilitation) programme will commence following diagnosis and continue up to the point of surgery and recommence for six weeks following surgery when deemed clinically fit to participate. assessments will occur at baseline, pre-surgery, post-surgery, and 6 weeks later and a follow up... mixed methods will be employed with patients taking part in self-report assessments, physical assessments, and qualitative interviews. the primary aim of the study is to assess the feasibility of the intervention and cardiorespiratory fitness pre-surgery. the secondary aims include assessing the effect of the intervention on physical health, psychological wellbeing, health-related quality of life, self-efficacy, nutrition, and serology markers. exploratory aims also include post-operative morbidity, health economics analysis and qualitative interview of patient experience.

Eligibility criteria:
inclusion criteria: * age ≥18 years, * multidisciplinary team referral for crs-hipec for colorectal/appendix/ovarian peritoneal disease or pseudomyxoma peritonei (+/- completed neoadjuvant cancer treatment) * who performance status ≤2. exclusion criteria: * inability to provide informed consent, * impaired cognitive function with a reduced ability to either understand advice /instructions from or communicate with the research team, * declined surgery, * surgery in less than 2 weeks * pregnancy or breastfeeding, * inability to participate in the exercise training (unable to perform the 6 minute walk test) * absolute contraindications to exercise testing, veganism.

Keywords: peritoneal malignancy
ultrasound guided ankle block versus medial forefoot block for forefoot surgery

Conditions: Pain Relief After Forefoot Surgery

Summary: forefoot surgery includes bunion surgery and similar reconstructive bone cutting surgery and is very painful. local anaesthetic nerve blocks have been used for many years to help alleviate pain following this surgery. the present study aims to compare a new ultrasound guided nerve block to a well established nerve stimulator guided technique. comparisons will include time taken to carry out the block, speed of onset of numbness and duration and quality of pain relief after surgery.


Eligibility criteria:
inclusion criteria: * fit adult patients requiring forefoot surgery with bone cutting. exclusion criteria: * morbid obesity (bmi \>40), known contraindications to regional anaesthesia

Keywords: anaesthetic techniques, regional; surgery orthopaedic
phase iia vorinostat (mk0683, suberoylanilide hydroxamic acid (saha)) study in lower risk myelodysplastic syndromes (0683-064)

Conditions: Myelodysplastic Syndromes; Blood Disease; Bone Marrow Disease

Summary: this study is to evaluate the efficacy, safety and tolerability of vorinostat in patients with lower risk myelodysplastic syndrome (mds).


Eligibility criteria:
inclusion criteria: patient is a male or female, at least 18 years of age with low or intermediate-1 risk myelodysplastic syndrome (mds) defined by the international prognostic scoring system * patient has previously untreated disease, or has received up to one prior treatment regimen for lower-risk myelodysplastic syndrome * patient has a performance status of equal to or less than 2 on the eastern cooperative oncology group performance scale * patient must have adequate organ function exclusion criteria: * patient has clinical evidence of central nervous system (cns) leukemia * patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the study * patient had prior treatment with a histone deacetylase inhibitor
sonography for covid-19 vaccines related reactive lymphadenopathy

Conditions: Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population

Summary: this study aimed to provide vast clinical information to facilitate breast sonographic examination for participants who underwent recent sars-cov-2 vaccination. among different sars-cov-2 vaccines in the asian taiwanese population, reactive axillary lymphadenopathy was investigated through breast sonographic findings and clinical data analysis. the sample included participants with recent vaccinations by different brands approved in taiwan.

study design and sample the retrospective study included female patients who underwent breast sonography in the radiology department of chi mei medical center between july 2021 and march 2022. the patients' breast cancer history and covid-19 vaccination history were collected and analyzed. analysis of breast sonography lymphadenopathy is defined as an enlarged lymph node with cortical thickening \>3 mm, either concentric or eccentric, with or without effacement of fatty hilum, or in-creased non-hilar vascularity on color or power doppler. the positive axillary lymph node findings were correlated by confirming a link to sars-cov-2 vaccination history within 90 days in the ipsilateral arm. statistical analysis all statistical analyses were performed using the r stats package. descriptive summaries were reported as mean ± standard deviation for continuous variables and percentages for categorical variables. for non-parametric variables, median with interquartile range and mann-whitney u test were used. statistical significance was set at a p-value \<0.05.

Eligibility criteria:
inclusion criteria: * female patients receiving breast sonography exclusion criteria: * receive covid 19 vaccine other than az, bnt, moderna * ongoing primary breast malignancy * history of malignancy other than primary breast malignancy

Keywords: breast neoplasms covid-19 vaccine lymphadenopathy